Under-reporting of harm in clinical trials.

[1]  Deborah Schrag,et al.  Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Vera-Badillo,et al.  Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[3]  J. Marshall,et al.  Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment , 2016, Journal of Cancer Research and Clinical Oncology.

[4]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[5]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[6]  Amy P Abernethy,et al.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.

[7]  A. Pandiella,et al.  Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses , 2015, Oncotarget.

[8]  A. Abernethy,et al.  Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. , 2015, Journal of oncology practice.

[9]  P. Karaca-Mandic,et al.  Drug Manufacturers' Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration. , 2015, JAMA internal medicine.

[10]  T. D. de Reijke,et al.  Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. , 2015, European urology.

[11]  A. Thompson,et al.  Do participants in adjuvant breast cancer trials reflect the breast cancer patient population? , 2015, European journal of cancer.

[12]  Gideon Blumenthal,et al.  Assessment of benefits and risks in development of targeted therapies for cancer — The view of regulatory authorities , 2015, Molecular oncology.

[13]  Joel Lexchin,et al.  Why are there deadly drugs? , 2015, BMC Medicine.

[14]  Gaetano Rocco,et al.  Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Amy P Abernethy,et al.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). , 2014, Journal of the National Cancer Institute.

[16]  P. Marchetti,et al.  Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. , 2014, Future oncology.

[17]  Douglas G. Altman,et al.  Evidence for the Selective Reporting of Analyses and Discrepancies in Clinical Trials: A Systematic Review of Cohort Studies of Clinical Trials , 2014, PLoS medicine.

[18]  I. Tannock,et al.  Comparison of results between the first and updated reports of phase III clinical trials (RCTs). , 2014 .

[19]  P. Ascierto,et al.  Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort , 2014, Journal of Translational Medicine.

[20]  D. Bertram,et al.  Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries , 2014, Drug Safety.

[21]  A. Rossi,et al.  Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice. , 2014, Translational lung cancer research.

[22]  J. Lexchin,et al.  Quality and Quantity of Information in Summary Basis of Decision Documents Issued by Health Canada , 2014, PloS one.

[23]  B. Djulbegovic,et al.  Treatment-related harms: what was planned and what was reported? National Cancer Institute's Co-operative group phase III randomized controlled trials: a systematic review. , 2014, Journal of clinical epidemiology.

[24]  I. Tannock,et al.  Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence , 2014, British Journal of Cancer.

[25]  W. Oh,et al.  Adverse event reporting in cancer clinical trial publications. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  I. Tannock,et al.  Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  E. Chen,et al.  Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Thierry Gil,et al.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.

[29]  C. Punt,et al.  Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands , 2013, Acta oncologica.

[30]  I. Tannock,et al.  Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Ethan Basch,et al.  Systematic Collection of Patient-Reported Adverse Drug Reactions: A Path to Patient-Centred Pharmacovigilance , 2013, Drug Safety.

[32]  L. Hazell,et al.  How Do Patients Contribute to Signal Detection? , 2013, Drug Safety.

[33]  M. Gönen,et al.  Reliability of adverse symptom event reporting by clinicians , 2012, Quality of Life Research.

[34]  Corneel Coens,et al.  Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. , 2011, Journal of the National Cancer Institute.

[35]  E. Basch,et al.  Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. , 2011, Journal of the National Cancer Institute.

[36]  D. Moher,et al.  Reporting quality of life in clinical trials: a CONSORT extension , 2011, The Lancet.

[37]  I. Tannock,et al.  Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Bezjak,et al.  Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers , 2011, Quality of Life Research.

[39]  Lisa Wang,et al.  Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  F. Shepherd,et al.  Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  G. Guyatt,et al.  Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. , 2010, JAMA.

[42]  Ethan Basch,et al.  The missing voice of patients in drug-safety reporting. , 2010, The New England journal of medicine.

[43]  Alexia Iasonos,et al.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. , 2009, Journal of the National Cancer Institute.

[44]  John P A Ioannidis,et al.  Adverse events in randomized trials: neglected, restricted, distorted, and silenced. , 2009, Archives of internal medicine.

[45]  Isabelle Boutron,et al.  Reporting of safety results in published reports of randomized controlled trials. , 2009, Archives of internal medicine.

[46]  H. Sorbye,et al.  Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients , 2009, Cancer.

[47]  Roger B. Davis,et al.  Clinicians' assessments of electronic medication safety alerts in ambulatory care. , 2009, Archives of internal medicine.

[48]  D. Cescon,et al.  Presentation of nonfinal results of randomized controlled trials at major oncology meetings. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Dennis P. West,et al.  Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. , 2008, The Lancet. Oncology.

[50]  Serguei V. S. Pakhomov,et al.  Agreement between patient-reported symptoms and their documentation in the medical record. , 2008, The American journal of managed care.

[51]  M. Halpern,et al.  Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? , 2008, CA: a cancer journal for clinicians.

[52]  Jesse A Berlin,et al.  Adverse event detection in drug development: recommendations and obligations beyond phase 3. , 2008, American journal of public health.

[53]  R. Kronmal,et al.  Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. , 2008, JAMA.

[54]  J. Avorn,et al.  Drug-review deadlines and safety problems. , 2008, The New England journal of medicine.

[55]  T. Fojo,et al.  Is there room for improvement in adverse event reporting in the era of targeted therapies? , 2008, Journal of the National Cancer Institute.

[56]  Ethan Basch,et al.  Patient-reported outcomes and the evolution of adverse event reporting in oncology. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  P. Hall,et al.  Noncancer causes of death in survivors of testicular cancer. , 2007, Journal of the National Cancer Institute.

[58]  M. Kris,et al.  Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. , 2006, The Lancet. Oncology.

[59]  A. Colevas,et al.  Adverse event reporting in publications compared with sponsor database for cancer clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Gordon H Guyatt,et al.  Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.

[61]  P. Lurie,et al.  Misleading data analyses in salmeterol (SMART) study , 2005, The Lancet.

[62]  D. Altman,et al.  Outcome selection bias in meta-analysis , 2005, Statistical methods in medical research.

[63]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[64]  J. Ioannidis,et al.  Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.

[65]  M. Mori,et al.  How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[67]  A. Hrõbjartsson,et al.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.

[68]  Sean A. Spence,et al.  Brave New Brain: Conquering Mental Illness in the Era of the Genome , 2001, BMJ : British Medical Journal.

[69]  J. Blay,et al.  The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  T. Postma,et al.  Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  T. Choueiri,et al.  Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  L. Hazell,et al.  Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.